![Abivax](/common/images/company/EU_ABVX.png)
Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1...
PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.5 | 4.05186385737 | 12.34 | 12.88 | 12.28 | 24467 | 12.60855048 | DE |
4 | 0.34 | 2.72 | 12.5 | 13.3 | 11.56 | 17458 | 12.62137298 | DE |
12 | -1.78 | -12.1751025992 | 14.62 | 15.42 | 11.56 | 20267 | 13.07662132 | DE |
26 | 2.86 | 28.6573146293 | 9.98 | 15.42 | 9.87 | 28207 | 12.74163785 | DE |
52 | -3.1 | -19.4479297365 | 15.94 | 19.18 | 7.89 | 35902 | 11.82687097 | DE |
156 | -17.66 | -57.9016393443 | 30.5 | 36.7 | 5.6 | 31673 | 13.55884509 | DE |
260 | 3.64 | 39.5652173913 | 9.2 | 39 | 5.6 | 32926 | 17.06432126 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.